Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : LastShadow's Position Trading -- Ignore unavailable to you. Want to Upgrade?

To: LastShadow who wrote (16792)	7/8/1999 3:59:00 PM
From: Redhook	Read Replies (1) \| Respond to of 43080

SWCM didn't last under 31 long. Took off over 32 now. I think it will see 36 tomorrow.

To: LastShadow who wrote (16792)	7/8/1999 4:09:00 PM
From: AlienTech	Respond to of 43080

=DJ Human Genome Stk -2: Study To Appear In Science Fri. NEW YORK (Dow Jones)--Shares of Human Genome Sciences Inc. (HGSI) were up nearly 4% Thursday after the company disclosed it had identified an immune stimulant that could help treat infectious diseases. The discovery of the stimulant - B Lymphocyte Stimulator, or BLyS - is scheduled to be reported in the July 9 issue of the journal Science. BLyS is a protein that spurs the body to create high levels of antibodies, the prime way the human immune system fights disease. Human Genome Sciences said that, in time, BLyS may be used to treat some immune deficiencies, to work in conjunction with vaccines, or to treat some forms of leukemia and lymphoma. The company's shares recently were up 1 /2, or 3.7%, at 42 3/8 on lighter than average volume. - Raymond Hennessey; 201-938-5240; raymond.hennessey@dowjones.com (END) DOW JONES NEWS 07-08-99 03:22 PM